Use of adjuvant chemotherapy in patients with stage III colon cancer in Puerto Rico: A population-based study.

This study aims to examine factors associated with the use of adjuvant chemotherapy and the use of oxaliplatin after curative resection in stage III colon cancer patients and assesses the effect of their use in three-year survival.This retrospective cohort study was conducted using Puerto Rico Centr...

Full description

Bibliographic Details
Main Authors: Karen J Ortiz-Ortiz, Guillermo Tortolero-Luna, Ruth Ríos-Motta, Alejandro Veintidós-Feliú, Robert Hunter-Mellado, Carlos R Torres-Cintrón, Tonatiuh Suárez-Ramos, Priscilla Magno
Format: Article
Language:English
Published: Public Library of Science (PLoS) 2018-01-01
Series:PLoS ONE
Online Access:http://europepmc.org/articles/PMC5870969?pdf=render
_version_ 1818431880226144256
author Karen J Ortiz-Ortiz
Guillermo Tortolero-Luna
Ruth Ríos-Motta
Alejandro Veintidós-Feliú
Robert Hunter-Mellado
Carlos R Torres-Cintrón
Tonatiuh Suárez-Ramos
Priscilla Magno
author_facet Karen J Ortiz-Ortiz
Guillermo Tortolero-Luna
Ruth Ríos-Motta
Alejandro Veintidós-Feliú
Robert Hunter-Mellado
Carlos R Torres-Cintrón
Tonatiuh Suárez-Ramos
Priscilla Magno
author_sort Karen J Ortiz-Ortiz
collection DOAJ
description This study aims to examine factors associated with the use of adjuvant chemotherapy and the use of oxaliplatin after curative resection in stage III colon cancer patients and assesses the effect of their use in three-year survival.This retrospective cohort study was conducted using Puerto Rico Central Cancer Registry-Health Insurance Linkage Database. The study cohort consisted of stage III colon cancer patients with a curative surgery in the period 2008-2012. Multivariate logistic regression was used to estimate adjusted odds ratios. Kaplan-Meier methods and Cox proportional hazards models were used to assess the association between adjuvant chemotherapy and oxaliplatin use and overall survival and risk of death, respectively.Overall, 75% of the study population received adjuvant chemotherapy during the study period. Factors statistically associated with receiving adjuvant chemotherapy within four months after resection included being married (adjusted odds ratio [AOR] 1.64; 95% CI 1.18-2.28; p = 0.003), and being enrolled in Medicare (AOR 1.68; 95% CI: 1.03-2.75; p = 0.039) or Medicaid and Medicare dual eligible (AOR 1.66; 95% CI: 1.06-2.60; p = 0.028). However, patients aged ≥70 years were less likely to receive adjuvant chemotherapy (AOR 0.22; 95%CI 0.14-0.36; p<0.001).We observed a significant reduction in mortality in adjuvant chemotherapy treated patients. Similarly, patients <70 years treated with oxaliplatin had significantly lower risk of death than those who did not, although for patients ≥70 years no statistical significance was achieved. Future studies should assess effective interventions to reduce barriers to access guideline-based recommended colon cancer treatment.
first_indexed 2024-12-14T15:56:20Z
format Article
id doaj.art-c078ee32025f4091a8a8519f853478ae
institution Directory Open Access Journal
issn 1932-6203
language English
last_indexed 2024-12-14T15:56:20Z
publishDate 2018-01-01
publisher Public Library of Science (PLoS)
record_format Article
series PLoS ONE
spelling doaj.art-c078ee32025f4091a8a8519f853478ae2022-12-21T22:55:15ZengPublic Library of Science (PLoS)PLoS ONE1932-62032018-01-01133e019441510.1371/journal.pone.0194415Use of adjuvant chemotherapy in patients with stage III colon cancer in Puerto Rico: A population-based study.Karen J Ortiz-OrtizGuillermo Tortolero-LunaRuth Ríos-MottaAlejandro Veintidós-FeliúRobert Hunter-MelladoCarlos R Torres-CintrónTonatiuh Suárez-RamosPriscilla MagnoThis study aims to examine factors associated with the use of adjuvant chemotherapy and the use of oxaliplatin after curative resection in stage III colon cancer patients and assesses the effect of their use in three-year survival.This retrospective cohort study was conducted using Puerto Rico Central Cancer Registry-Health Insurance Linkage Database. The study cohort consisted of stage III colon cancer patients with a curative surgery in the period 2008-2012. Multivariate logistic regression was used to estimate adjusted odds ratios. Kaplan-Meier methods and Cox proportional hazards models were used to assess the association between adjuvant chemotherapy and oxaliplatin use and overall survival and risk of death, respectively.Overall, 75% of the study population received adjuvant chemotherapy during the study period. Factors statistically associated with receiving adjuvant chemotherapy within four months after resection included being married (adjusted odds ratio [AOR] 1.64; 95% CI 1.18-2.28; p = 0.003), and being enrolled in Medicare (AOR 1.68; 95% CI: 1.03-2.75; p = 0.039) or Medicaid and Medicare dual eligible (AOR 1.66; 95% CI: 1.06-2.60; p = 0.028). However, patients aged ≥70 years were less likely to receive adjuvant chemotherapy (AOR 0.22; 95%CI 0.14-0.36; p<0.001).We observed a significant reduction in mortality in adjuvant chemotherapy treated patients. Similarly, patients <70 years treated with oxaliplatin had significantly lower risk of death than those who did not, although for patients ≥70 years no statistical significance was achieved. Future studies should assess effective interventions to reduce barriers to access guideline-based recommended colon cancer treatment.http://europepmc.org/articles/PMC5870969?pdf=render
spellingShingle Karen J Ortiz-Ortiz
Guillermo Tortolero-Luna
Ruth Ríos-Motta
Alejandro Veintidós-Feliú
Robert Hunter-Mellado
Carlos R Torres-Cintrón
Tonatiuh Suárez-Ramos
Priscilla Magno
Use of adjuvant chemotherapy in patients with stage III colon cancer in Puerto Rico: A population-based study.
PLoS ONE
title Use of adjuvant chemotherapy in patients with stage III colon cancer in Puerto Rico: A population-based study.
title_full Use of adjuvant chemotherapy in patients with stage III colon cancer in Puerto Rico: A population-based study.
title_fullStr Use of adjuvant chemotherapy in patients with stage III colon cancer in Puerto Rico: A population-based study.
title_full_unstemmed Use of adjuvant chemotherapy in patients with stage III colon cancer in Puerto Rico: A population-based study.
title_short Use of adjuvant chemotherapy in patients with stage III colon cancer in Puerto Rico: A population-based study.
title_sort use of adjuvant chemotherapy in patients with stage iii colon cancer in puerto rico a population based study
url http://europepmc.org/articles/PMC5870969?pdf=render
work_keys_str_mv AT karenjortizortiz useofadjuvantchemotherapyinpatientswithstageiiicoloncancerinpuertoricoapopulationbasedstudy
AT guillermotortoleroluna useofadjuvantchemotherapyinpatientswithstageiiicoloncancerinpuertoricoapopulationbasedstudy
AT ruthriosmotta useofadjuvantchemotherapyinpatientswithstageiiicoloncancerinpuertoricoapopulationbasedstudy
AT alejandroveintidosfeliu useofadjuvantchemotherapyinpatientswithstageiiicoloncancerinpuertoricoapopulationbasedstudy
AT roberthuntermellado useofadjuvantchemotherapyinpatientswithstageiiicoloncancerinpuertoricoapopulationbasedstudy
AT carlosrtorrescintron useofadjuvantchemotherapyinpatientswithstageiiicoloncancerinpuertoricoapopulationbasedstudy
AT tonatiuhsuarezramos useofadjuvantchemotherapyinpatientswithstageiiicoloncancerinpuertoricoapopulationbasedstudy
AT priscillamagno useofadjuvantchemotherapyinpatientswithstageiiicoloncancerinpuertoricoapopulationbasedstudy